Pascal Biosciences
  • Home
  • Company
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact
  • AGM December 18, 2020
Skip to content
Home / News / Page 3

News

23Apr 2019

Pascal Biosciences Provides Corporate Update for First Quarter of 2019

  • Apr 23, 2019
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, April 23, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today provided a corporate update for the first quarter of 2019. “We’ve made significant strides since…

Read More

1Apr 2019

Pascal Biosciences names Carl Weissman acting President

  • Apr 1, 2019
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, April 1, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced that Carl Weissman has joined the company in the role of acting President. Weissman…

Read More

18Mar 2019

Pascal Biosciences Partners with Mitacs to Support Innovative Cancer Research at University of British Columbia

  • Mar 18, 2019
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, March 18, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced a partnership with Mitacs for a multi-year cancer research project at the University of…

Read More

6Mar 2019

Pascal featured on Cultivate Webcast

  • Mar 6, 2019
  • In the News

An interview with Dr. Patrick Gray, CEO of Pascal Biosciences, is featured in the latest episode of Cultivate – a news webcast distributed by CannabisTech.com, an online publication covering science and technology news in the cannabis and tech industries. We invite you to…

Read More

24Jan 2019

Pascal Biosciences Commences Cannabinoid Testing of Human Volunteers and Patients

  • Jan 24, 2019
  • Press Releases

VANCOUVER, British Columbia, and SEATTLE, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the testing of cannabinoids in human subjects for its immune stimulatory program in cancer. Furthermore,…

Read More

28Dec 2018

Pascal Biosciences Provides Year-End Investor Update and Reviews Upcoming Milestones

  • Dec 28, 2018
  • Press Releases

- 2018 pipeline expansion includes lead cannabinoid-based cancer therapeutic - Clinical trial in glioblastoma to begin in 2019 VANCOUVER, British Columbia and SEATTLE, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development…

Read More

11Dec 2018

Pascal Biosciences Announces Year-End Investor Update Webcast

  • Dec 11, 2018
  • Press Releases

Advancement of Cannabinoid Cancer Programs and Corporate Review to be Presented Scheduled for Dec. 17, 2018 at 1:30 p.m. Pacific VANCOUVER, British Columbia and SEATTLE, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug…

Read More

28Nov 2018

Pascal Biosciences Expands Leadership Team to Support Strategic Advancement of Its Cannabinoid Based Programs

  • Nov 28, 2018
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, November 28, 2018 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the strengthening of its leadership team with the appointments of seasoned executives in therapeutic…

Read More

10Nov 2018

Pascal Biosciences CEO interview on Canada Pot Talks 107.7 Pulse FM (minute 46)

  • Nov 10, 2018
  • In the News

Listen to an interview with CEO Patrick Gray on Canada Pot Talks. Canada Pot Talks - November 10th 2018

Read More

8Nov 2018

CFN's exclusive Interview with Pascal Biosciences

  • Nov 8, 2018
  • In the News

CEO Patrick Gray sat down with CFN Media for an exclusive interview. Read the full interview here.  

Read More

Page Navigation

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

Recent Posts

  • Pascal Biosciences to Present at Cannabinoid Derived Pharmaceuticals Industry Review Summit
  • Pascal Amends Terms of Non-brokered Private Placement
  • Pascal Biosciences and SōRSE Technology Optimize Cannabinoid Formulation for Clinical Development of Cancer Treatment
  • Pascal Biosciences Appoints Mark van der Horst as Vice President of Corporate Communications
  • Pascal Announces Non-Brokered Private Placement

Categories

  • In the News
  • Press Releases
  • Uncategorized

Archives

  • January 2021
  • December 2020
  • November 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • March 2020
  • October 2019
  • September 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • July 2018
  • June 2018
  • February 2018
  • December 2017
  • September 2017
  • May 2017
  • March 2017
  • November 2016
  • October 2016
  • September 2016

About

Pascal Biosciences Inc. (TSX-V: PAS, FSE:6PB.F) is a biotechnology company focused on developing cannabinoid-based and targeted therapeutics to fight cancer.

Locations

USA

Fluke Hall, Suite 304
Box 352141
4000 Mason Road
Seattle, WA 98195-2141

Canada

280 7th Avenue East
Vancouver, BC V5T 0B4

Contact

Phone

206.221.3443

Email

info@pascalbiosciences.com

Investors

invest@pascalbiosciences.com

Partnering & Business Development

bd@pascalbiosciences.com

Let's Connect

  • Facebook
  • Twitter
  • Linked
  • Home
  • Company
  • Programs
  • News
  • Investors
  • Contact
  • Disclaimer
  • Legal Notices

© Copyright 2021 Pascal Biosciences Inc. All rights reserved.   Seattle Website Design by Jordan Crown Design

  • Home
  • Company
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact
  • AGM December 18, 2020

‹ › ×